JAKMIP2-AS1

Across TCGA pan-cancer cohorts, JAKMIP2-AS1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of JAKMIP2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where JAKMIP2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types JAKMIP2-AS1 is over-expressed in tumor, although a few such as LIHC and BRCA show the opposite, repressed pattern.

KIRC, BLCA, and LIHC are the cancer types where JAKMIP2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JAKMIP2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+0.036	<.001	9	view →
BLCA	Male	III,IV	+0.075	.034	3	view →
LIHC	All	II,III,IV	−0.139	.004	2	view →
BRCA	All	III,IV	−0.024	.033	2	view →
CHOL	All	All	−0.188	.016	1	view →
KICH	All	All	+0.009	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

JAKMIP2-AS1–KIRC

Open the KIRC breakdown →